A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma

Phase 2 Unknown 150 enrolled Genrix (Shanghai) Biopharmaceutical Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of GR1802 injection in comparison to placebo in patients with atopic dermatitis. Patients will receive GR1802 injection or Placebo every 2 Weeks.

Timeline

Start: 2022-07-19
Primary completion: 2025-03-31
Completion: 2025-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GR1802	Monoclonal antibody	150 mg	Subcutaneous
Subject	GR1802	Monoclonal antibody	300 mg	Subcutaneous

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma

Summary

Timeline

Drugs

Indications